VRC 01LS
Alternative Names: VRC-HIVMAB060-00-AB; VRC-HIVMAB060-00-AB (VRC01); VRC01LSLatest Information Update: 28 Apr 2023
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer National Institute of Allergy and Infectious Diseases; Xencor
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, In adults) in Kenya (IV, Infusion)
- 28 Apr 2023 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, In adults) in Tanzania (IV, Infusion)
- 28 Apr 2023 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, In adults) in Thailand (IV, Infusion)